AR and prostate carcinoma: Chen et al. [19] and Zgarbová and Vrzal [23] demonstrated that AhR antagonists like carbidopa and natural AhR agonists, respectively, can effectively reduce AR activity and prostate cancer cell viability, highlighting the potential for these compounds in therapeutic applications.